Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
The presentation will include new data from the ongoing Phase 1 study evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
- The presentation will include new data from the ongoing Phase 1 study evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
- Data supporting the fixed dose selection for Part 2, the single-dose expansion cohort of the polyneuropathy arm, will also be presented.
- There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and 500,000 people with ATTRwt amyloidosis.
- Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.